Virtus ETF Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Virtus ETF Advisers’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,581	Closed	-$113K	–	416
2021 Q3	$113K	Sell	5,581 -299	-5%	-$8.26K	0.05%	373
2021 Q2	$219K	Sell	5,880 -6,272	-52%	-$192K	0.09%	280
2021 Q1	$311K	Buy	12,152 +213	+2%	+$5.44K	0.13%	236
2020 Q4	$263K	Sell	11,939 -3,425	-22%	-$75.4K	0.11%	293
2020 Q3	$276K	Sell	15,364 -2,097	-12%	-$43.4K	0.14%	244
2020 Q2	$444K	Buy	17,461 +4,031	+30%	+$86.8K	0.21%	166
2020 Q1	$247K	Sell	13,430 -1,941	-13%	-$37.7K	0.1%	254
2019 Q4	$339K	Sell	15,371 -1,744	-10%	-$35.1K	0.06%	286
2019 Q3	$246K	Sell	17,115 -953	-5%	-$13.6K	0.05%	216
2019 Q2	$285K	Buy	+18,068	New	+$246K	0.06%	238
2019 Q1	–	Sell	-24,457	Closed	-$261K	–	288
2018 Q4	$261K	Buy	+24,457	New	+$322K	0.04%	155

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Virtus ETF Advisers's DRNA Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 5,581 shares — an estimated $113K sold.

Virtus ETF Advisers first reported a position in DRNA in Q4 2018 and held it in 11 quarters. The position peaked at $444K in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Virtus ETF Advisers reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Virtus ETF Advisers sold 5,581 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $113K.
Virtus ETF Advisers first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 11 quarters.
Virtus ETF Advisers's Dicerna Pharmaceuticals, Inc. position peaked at $444K in Q2 2020.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.